A detailed history of Aqr Capital Management LLC transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Aqr Capital Management LLC holds 1,519,711 shares of CHRS stock, worth $2.39 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,519,711
Previous 719,999 111.07%
Holding current value
$2.39 Million
Previous $1.25 Million 26.91%
% of portfolio
0.0%
Previous 0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.99 - $1.8 $791,714 - $1.44 Million
799,712 Added 111.07%
1,519,711 $1.58 Million
Q2 2024

Aug 14, 2024

BUY
$1.58 - $2.51 $1.14 Million - $1.81 Million
719,999 New
719,999 $1.25 Million
Q4 2023

Feb 14, 2024

BUY
$1.59 - $3.85 $525,070 - $1.27 Million
330,233 Added 802.84%
371,366 $1.24 Million
Q3 2023

Nov 14, 2023

SELL
$3.74 - $5.45 $7,790 - $11,352
-2,083 Reduced 4.82%
41,133 $153,000
Q2 2023

Aug 14, 2023

SELL
$3.79 - $8.3 $102,330 - $224,100
-27,000 Reduced 38.45%
43,216 $184,000
Q1 2023

May 15, 2023

SELL
$5.89 - $10.52 $87,030 - $155,443
-14,776 Reduced 17.39%
70,216 $480,000
Q4 2022

Feb 14, 2023

BUY
$5.69 - $10.07 $271,242 - $480,036
47,670 Added 127.73%
84,992 $673,000
Q3 2022

Nov 14, 2022

SELL
$7.17 - $13.87 $61,375 - $118,727
-8,560 Reduced 18.66%
37,322 $359,000
Q2 2022

Aug 15, 2022

SELL
$5.86 - $13.23 $186,500 - $421,057
-31,826 Reduced 40.96%
45,882 $332,000
Q1 2022

May 16, 2022

BUY
$10.92 - $16.41 $660,026 - $991,853
60,442 Added 350.06%
77,708 $1 Million
Q4 2021

Feb 14, 2022

SELL
$15.81 - $18.99 $40,536 - $48,690
-2,564 Reduced 12.93%
17,266 $276,000
Q3 2021

Nov 15, 2021

SELL
$12.68 - $17.79 $91,004 - $127,678
-7,177 Reduced 26.57%
19,830 $319,000
Q2 2021

Aug 16, 2021

SELL
$12.95 - $15.41 $1.09 Million - $1.3 Million
-84,533 Reduced 75.79%
27,007 $374,000
Q1 2021

May 17, 2021

BUY
$14.42 - $21.39 $233,416 - $346,239
16,187 Added 16.98%
111,540 $1.63 Million
Q4 2020

Feb 16, 2021

SELL
$16.56 - $18.94 $280,609 - $320,938
-16,945 Reduced 15.09%
95,353 $1.66 Million
Q3 2020

Nov 16, 2020

SELL
$17.41 - $19.89 $1.88 Million - $2.14 Million
-107,796 Reduced 48.98%
112,298 $2.06 Million
Q2 2020

Aug 17, 2020

BUY
$14.43 - $19.16 $1.86 Million - $2.47 Million
128,672 Added 140.75%
220,094 $3.93 Million
Q1 2020

May 15, 2020

BUY
$11.67 - $22.53 $632,945 - $1.22 Million
54,237 Added 145.86%
91,422 $1.48 Million
Q4 2019

Feb 14, 2020

BUY
$16.33 - $21.37 $314,417 - $411,457
19,254 Added 107.38%
37,185 $670,000
Q3 2019

Nov 14, 2019

BUY
$16.3 - $23.37 $58,142 - $83,360
3,567 Added 24.83%
17,931 $363,000
Q2 2019

Aug 14, 2019

SELL
$13.1 - $22.1 $116,629 - $196,756
-8,903 Reduced 38.26%
14,364 $317,000
Q1 2019

May 14, 2019

SELL
$8.38 - $15.5 $135,404 - $250,449
-16,158 Reduced 40.98%
23,267 $317,000
Q4 2018

Feb 14, 2019

BUY
$8.65 - $16.28 $341,026 - $641,839
39,425 New
39,425 $357,000
Q4 2017

Feb 14, 2018

SELL
$8.35 - $14.4 $224,740 - $387,576
-26,915 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$11.1 - $14.5 $298,756 - $390,267
26,915
26,915 $359,000

Others Institutions Holding CHRS

About Coherus BioSciences, Inc.


  • Ticker CHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,724,600
  • Market Cap $122M
  • Description
  • Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...
More about CHRS
Track This Portfolio

Track Aqr Capital Management LLC Portfolio

Follow Aqr Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aqr Capital Management LLC with notifications on news.